NASDAQ$LFST
LifeStance Health Group Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
LifeStance's Q3 2024 performance exceeded expectations, driven by revenue growth and improved profitability.
LifeStance Health Group reported a 19% increase in revenue to $312.7 million for Q3 2024. The company's net loss significantly improved to $6.0 million, and Adjusted EBITDA increased by 110% to $30.7 million. LifeStance also raised its full-year 2024 revenue and Adjusted EBITDA expectations.
- Revenue increased by 19% to $312.7 million.
- The clinician base grew by 13% to 7,269 clinicians.
- Net loss improved to $6.0 million from $61.6 million.
- Adjusted EBITDA increased by 110% to $30.7 million.
Headline financials
Revenue & EPS history
LifeStance · Revenue · Quarterly
$313M
Forward guidance
LifeStance raised its full year revenue to $1.228 billion to $1.248 billion; raising Center Margin to $382 million to $398 million; and raising Adjusted EBITDA to $105 million to $115 million. Additionally, the Company continues to expect to generate positive Free Cash Flow for the full year. For the fourth quarter of 2024, the Company expects total revenue of $302.5 million to $322.5 million, Center Margin of $89 million to $105 million, and Adjusted EBITDA of $18 million to $28 million.
Tailwinds
- Raising full year revenue to $1.228 billion to $1.248 billion
- Raising Center Margin to $382 million to $398 million
- Raising Adjusted EBITDA to $105 million to $115 million
- Continue to expect to generate positive Free Cash Flow for the full year
- Expect total revenue of $302.5 million to $322.5 million for Q4 2024
Headwinds
- Center Margin of $89 million to $105 million
- Adjusted EBITDA of $18 million to $28 million
- Potential rate pressure
- Competition in the mental healthcare industry
- Dependence on relationships with supported practices
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-4.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.2%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+24.6%
Q4 2023
Best reaction
-49.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +19.8% | +7.7% | +0.5% | |
| Q4 2025 | +4.3% | +0.0% | -11.5% | |
| Q3 2025 | -3.6% | +29.1% | +30.1% | |
| Q1 2025 | -16.0% | -10.7% | -10.8% | |
| Q4 2024 | +3.1% | +6.8% | -10.8% | |
| Q3 2024 | +3.2% | +3.8% | +2.9% | |
| Q2 2024 | +1.6% | +6.0% | +26.1% | |
| Q1 2024 | -1.7% | +5.9% | -19.1% | |
| Q4 2023 | +24.6% | +21.8% | -3.4% | |
| Q3 2023 | -9.4% | -8.9% | +7.9% | |
| Q2 2023 | -5.0% | -7.4% | -17.1% | |
| Q1 2023 | -1.4% | +1.1% | +1.7% | |
| Q4 2022 | +22.2% | +23.8% | +65.6% | |
| Q3 2022 | -30.4% | -15.9% | -23.0% | |
| Q2 2022 | +6.2% | +10.8% | +29.3% | |
| Q1 2022 | -13.9% | +0.4% | +10.1% | |
| Q4 2021 | -12.7% | -5.9% | +4.2% | |
| Q3 2021 | -27.3% | -22.8% | -29.1% | |
| Q2 2021 | -49.7% | -40.6% | -30.2% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro